10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025

In the paper

“Approximately 45% of people admitted for HFpEF have diabetes, and most people with HFpEF have obesity (320,321).”

What the sources say

• ?Not checked — no full text of the sourcecites [320] Echouffo-Tcheugui, 2016, Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry, Am Heart J source
• Disputed

  The Results > Baseline Characteristics section reports that 41.3% of the I-PRESERVE HFpEF cohort had obesity (BMI >30 kg/m²), not most patients. The Discussion > Clinical and Demographic Characteristics section says more than 83% were overweight or obese combined; that does not establish that most had obesity. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  cites [321] Haass, 2011, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial, Circ Heart Fail sourceExperimental — accuracy not yet measured

In the paper

“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”

What the sources say

• Supported

  The Results section (Serious Adverse Events) states that hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure occurred more frequently in the intensive-treatment group. The Discussion says these adverse events should be weighed against the cardiovascular and mortality benefits of intensive blood-pressure control. (LLM, conf=0.95)

  cites [38] Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med source

In the paper

“Adverse events attributed to blood pressure treatment, including hypotension, syncope, bradycardia, hyperkalemia, and elevations in serum creatinine, occurred more frequently in the intensive treatment arm than in the standard therapy arm.”

What the sources say

• Partly supported

  The Results > Adverse Events section reports more serious events attributed to antihypertensive treatment and more serum-creatinine elevations in the intensive group. It reports hypokalemia, not the claimed hyperkalemia, and does not establish higher rates of syncope or bradycardia; symptoms of orthostatic hypotension were similar between groups. No page number is available in our copy. (LLM, conf=0.88)

  cites [40] Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”

What the sources say

• Supported

  The Methods (Study Outcomes; page unavailable) define the primary composite outcome as myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, or cardiovascular death. The Results (Clinical Outcomes; page unavailable) report a hazard ratio of 0.75 for intensive versus standard treatment, and the Discussion explicitly describes this as a 25% lower relative risk. (LLM, conf=0.95)

  cites [38] Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med source

In the paper

“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”

What the sources say

• Partly supported

  The Discussion (page not provided) reports substantial excess rates of cardiovascular outcomes in people with type 1 or type 2 diabetes, supporting the importance of cardiovascular disease as a source of morbidity and mortality. The paper does not establish that ASCVD is the leading cause, and its Outcomes section (page not provided) does not give the cited sentence’s broad definition of ASCVD. (LLM, conf=0.78)

  cites [1] Rawshani, 2017, Mortality and cardiovascular disease in type 1 and type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“In addition, people with diabetes are at risk for developing structural heart disease and HFrEF in the absence of obstructive coronary artery disease (14).”

What the sources say

• Supported

  The Epidemiology of Diabetes-Associated HF section reports increased heart-failure incidence in people with diabetes and recognizes HFrEF among the associated presentations. The opening section describes diabetic cardiomyopathy as distinct from coronary disease and says that the most common causes of heart failure are nonischemic; the review also describes structural myocardial changes in diabetes. Together, these passages support the stated risk without requiring obstructive coronary artery disease. (LLM, conf=0.84)

  cites [14] Marwick, 2018, Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy, J Am Coll Cardiol source

In the paper

“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”

What the sources say

• Supported

  The Discussion (page unavailable) reports marked reductions in mortality and cardiovascular complications among adults with both type 1 and type 2 diabetes from 1998 to 2014. It also identifies improved management of multiple risk factors as a likely contributor, while noting that other advances may have played a role. (LLM, conf=0.91)

  cites [1] Rawshani, 2017, Mortality and cardiovascular disease in type 1 and type 2 diabetes, N Engl J Med source

In the paper

“There is an increasing appreciation of the common pathophysiology and interrelationship of cardiometabolic risk factors leading to both adverse cardiovascular and adverse kidney outcomes in people with diabetes, including ASCVD, heart failure, and chronic kidney disease (CKD) (16).”

What the sources say

• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [16] Sperling, 2015, The CardioMetabolic Health Alliance: working toward a new care model for the metabolic syndrome, J Am Coll Cardiol sourceExperimental — accuracy not yet measured

In the paper

“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”

What the sources say

• Supported

  The Conclusions (p. 1) state that patients with type 2 diabetes whose five risk-factor variables were within target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke compared with the general population. The Results (p. 1) report hazard ratios of 1.06, 0.84, and 0.95, respectively, consistent with the citing sentence. (LLM, conf=0.93)

  cites [6] Rawshani, 2018, Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med source

In the paper

“The primary composite outcome of nonfatal MI, nonfatal stroke, or death from cardiovascular causes was not significantly reduced in the intensive treatment group.”

What the sources say

• Supported

  The Results (Clinical Outcomes) define the primary composite as nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death and report no significant difference between intensive and standard therapy (P = 0.20). The Discussion likewise states that intensive treatment did not significantly reduce the primary cardiovascular outcome. (LLM, conf=0.95)

  cites [40] Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med source

In the paper

“ACCORD BP provides the strongest direct assessment of the benefits and risks of intensive blood pressure management in people with type 2 diabetes (40).”

What the sources say

• Supported

  The Methods (Trial Procedures) describe ACCORD BP as a randomized comparison of intensive and standard blood-pressure targets, and the Discussion reports both cardiovascular outcomes and possible harms in patients with type 2 diabetes. The paper compares its design with earlier trials, although calling it the “strongest” assessment is the citing authors’ appraisal rather than the paper’s wording. (LLM, conf=0.85)

  cites [40] Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med source

In the paper

“The prespecified secondary outcome of stroke was significantly reduced by 41% in the intensive treatment group.”

What the sources say

• Supported

  The Methods (Trial Outcomes) identify fatal or nonfatal stroke as a prespecified secondary outcome. The Results (Clinical Outcomes) report a nominally significant reduction in total stroke with intensive treatment (hazard ratio 0.59; P = 0.01), equivalent to a 41% relative reduction. (LLM, conf=0.94)

  cites [40] Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med source

In the paper

“A systematic review of 10 randomized controlled trials reported that compared with control diet, the modified Dietary Approaches to Stop Hypertension (DASH) eating pattern could reduce mean systolic (À3.26 mmHg [95% CI À5.58 to À0.94 mmHg]; P = 0.006) and diastolic (À2.07 mmHg [95% CI À3.68 to À0.46 mmHg]; P = 0.01) blood pressure (60).”

What the sources say

• Supported

  The Abstract reports 10 included RCTs and gives the cited systolic and diastolic reductions, confidence intervals, and P values compared with a control diet. The Results section (“Effect on BP”) corroborates both mean differences and confidence intervals. (LLM, conf=0.95)

  cites [60] Guo, 2021, Effects of the modified DASH diet on adults with elevated blood pressure or hypertension: a systematic review and meta-analysis, Front Nutr source

In the paper

“Secondary analyses of ACCORD BP and SPRINT suggest that clinical factors can help identify individuals more likely to benefit from and less likely to be harmed by intensive blood pressure management (46,47).”

What the sources say

• Supported

  The Abstract’s Conclusions say the predictive models identified subgroups in both SPRINT and ACCORD-BP with differing cardiovascular benefit and serious-adverse-event risk from intensive blood pressure treatment. The Discussion adds that considering clinical factors in combination explained variation in benefit and harm. (LLM, conf=0.93)

  cites [46] Basu, 2017, Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials, PLoS Med source
• Supported

  This source supports the SPRINT portion of the jointly cited claim. Its Discussion reports that stratifying SPRINT participants by estimated 10-year cardiovascular risk identified groups with more benefit than harm, or more harm than benefit, from intensive treatment. The paper does not need to establish the ACCORD BP portion, which is also cited separately. (LLM, conf=0.92)

  cites [47] Phillips, 2018, Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension, J Am Coll Cardiol source

In the paper

“Older individuals and those with CKD and frailty have been shown to be at higher risk of adverse effects of intensive blood pressure management (49).”

What the sources say

• Partly supported

  The Results (page unavailable in our copy) report higher risks of serious adverse events involving syncope, hypotension, and falls among participants with CKD or frailty and among older participants. But those are higher event risks, not evidence that intensive treatment caused a greater increase in risk in these groups: the Results found no treatment interaction by age or frailty. Intensive treatment increased hypotension risk overall, possibly increased syncope risk, and did not increase falls. (LLM, conf=0.88)

  cites [49] Sink, 2018, Syncope, hypotension, and falls in the treatment of hypertension: results from the randomized clinical systolic blood pressure intervention trial, J Am Geriatr Soc sourceExperimental — accuracy not yet measured

In the paper

“For individuals with albuminuria (urine albumin-to-creatinine ratio [UACR] $30 mg/g), initial treatment should include an ACE inhibitor or ARB to reduce the risk of progressive kidney disease (21) (Fig. 10.2).”

What the sources say

• Supported

  The “Classes of Antihypertensive Medications” section states the claim nearly verbatim: for patients with UACR ≥30 mg/g creatinine, initial hypertension treatment should include an ACE inhibitor or ARB to reduce the risk of progressive kidney disease. The recommendation is made in the context of treating hypertension in people with diabetes. (LLM, conf=0.95)

  cites [21] de Boer, 2017, Diabetes and hypertension: a position statement by the American Diabetes Association, Diabetes Care source

In the paper

“Use of internet or mobile-based digital platforms to reinforce healthy behaviors may be considered as a component of care, as these interventions have been found to enhance the efficacy of medical therapy for hypertension (61,62).”

What the sources say

• Partly supported

  The Results (Primary outcome of intervention; page not provided) report greater reductions in systolic and diastolic blood pressure with mHealth interventions than with traditional treatment. The Discussion also says telemedicine and mobile-phone text messages improved blood-pressure levels. The paper does not establish that reinforcing healthy behaviors specifically enhanced the efficacy of medical therapy, rather than improving blood-pressure outcomes more generally. (LLM, conf=0.84)

  cites [61] Mao, 2020, Impact and efficacy of mobile health intervention in the management of diabetes and hypertension: a systematic review and meta-analysis, BMJ Open Diabetes Res Care sourceExperimental — accuracy not yet measured
• Supported

  The Discussion (page not supplied) states that digital counselling optimized the efficacy of antihypertensive medical therapy in the reviewed trials. It reports a greater systolic blood-pressure reduction with digital interventions than with controls. (LLM, conf=0.93)

  cites [62] Stogios, 2020, Advancing digital health interventions as a clinically applied science for blood pressure reduction: a systematic review and meta-analysis, Can J Cardiol source

In the paper

“Absolute benefit from blood pressure reduction correlated with absolute baseline cardiovascular risk in SPRINT and in earlier clinical trials conducted at higher baseline blood pressure levels (47,48).”

What the sources say

• Partly supported

  The Results (page unavailable) report that absolute risk reduction increased across baseline CVD-risk quartiles in SPRINT. The Discussion (page unavailable) says earlier analyses found the greatest absolute risk reduction in those at greatest baseline risk, and separately describes earlier trials with higher blood pressures. It does not establish that those particular earlier trials showed the claimed risk–benefit relationship. (LLM, conf=0.83)

  cites [47] Phillips, 2018, Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [48] Blood Pressure Lowering Treatment Trialists' Collaboration, 2014, Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet source

In the paper

“In individuals receiving ACE inhibitor or ARB therapy, continuation of those medications as kidney function declines to estimated glomerular filtration rate (eGFR) <30 mL/min/ 1.73 m 2 may provide cardiovascular benefit without significantly increasing the risk of end-stage kidney disease (74).”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [74] Qiao, 2020, Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate, JAMA Intern Med source

In the paper

“Based on these analyses, antihypertensive treatment appears to be most beneficial when mean baseline blood pressure is $140/90 mmHg (20,31,32,(34)(35)(36).”

What the sources say

• ?Not checked — no full text of the sourcecites [20] Whelton, 2018, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol source
• ?Not checked — no full text of the sourcecites [31] Emdin, 2015, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis, JAMA source
• Partly supported

  The Authors’ conclusions (page unavailable) say that randomized-trial evidence does not support treatment targets below 140/90 mmHg in people with diabetes. That supports a point about treatment targets, but the review does not establish that antihypertensive treatment is most beneficial at a mean baseline blood pressure of 140/90 mmHg or report a meta-analysis stratified by baseline pressure. (LLM, conf=0.78)

  cites [32] Arguedas, 2013, Blood pressure targets for hypertension in people with diabetes mellitus, Cochrane Database Syst Rev sourceExperimental — accuracy not yet measured

In the paper

“However, ACCORD BP demonstrated that intensive blood pressure lowering decreased the risk of cardiovascular events irrespective of baseline diastolic blood pressure in individuals who also received standard glycemic management (51).”

What the sources say

• Supported

  The Conclusions state that, in people with type 2 diabetes receiving standard glycemic control, intensive systolic blood pressure lowering decreased the risk of the cardiovascular composite end point irrespective of baseline diastolic blood pressure. This directly supports the attributed claim. (LLM, conf=0.95)

  cites [51] Ilkun, 2020, The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes, Diabetes Care source

In the paper

“inhibitors and ARBs in combination, or the combination of an ACE inhibitor or ARB and a direct renin inhibitor, is contraindicated given the lack of added ASCVD benefit and increased rate of adverse events-namely, hyperkalemia, syncope, and AKI (78)(79)(80).”

What the sources say

• Partly supported

  Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable, 1 not checked. Expand the claim to see per-atom verdicts.

  cites [78] Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [79] Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med source
• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [80] Makani, 2013, Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials, BMJ sourceExperimental — accuracy not yet measured

In the paper

“The primary outcome, a composite of preeclampsia with severe features, medically indicated preterm birth at <35 weeks of gestation, placental abruption, or fetal or neonatal death, occurred in 30.2% of female participants in the active treatment group versus 37.0% in the control group (P < 0.001).”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [55] Tita, 2022, Treatment for mild chronic hypertension during pregnancy, N Engl J Med source

In the paper

“The addition of the PCSK9 inhibitors evolocumab and alirocumab to maximum tolerated doses of statin therapy in participants who were at high risk for ASCVD demonstrated an average reduction in LDL cholesterol ranging from 36% to 59% (126,127).”

What the sources say

• ?Not checked — no full text of the sourcecites [126] Moriarty, 2014, Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial, J Clin Lipidol source
• Partly supported

  The Discussion says the LDL-C reductions were largely achieved in patients already receiving stable statin treatment, and the Results report substantial reductions with both evolocumab and alirocumab. However, the paper does not establish a 36%–59% average reduction specifically among high-ASCVD-risk participants taking maximally tolerated statin doses; its 36.3% figure compares evolocumab with ezetimibe, not with statin therapy alone. (LLM, conf=0.88)

  cites [127] Zhang, 2015, Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials, BMC Med sourceExperimental — accuracy not yet measured

In the paper

“After the 24 weeks, alirocumab lowered LDL cholesterol levels by 54.8% versus 20.1% with ezetimibe.”

What the sources say

• Supported

  Figure 2 reports week-24 LDL-C reductions of 54.8% with alirocumab and 20.1% with ezetimibe. Its caption identifies these as on-treatment results; the paper reports different percentages for its primary intent-to-treat analysis. Page numbers are not available in our copy. (LLM, conf=0.92)

  cites [134] Moriarty, 2015, Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial, J Clin Lipidol source

In the paper

“Subgroup analyses of people with diabetes in larger trials (101-105) and trials in people with diabetes (106,107) showed significant primary and secondary prevention of ASCVD events and CHD death in people with diabetes.”

What the sources say

• ?Not checked — no full text of the sourcecites [101] Pyŏrälä, 1997, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), Diabetes Care source
• ?Not checked — no full text of the sourcecites [102] Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet source
• Partly supported

  The Results report a significant reduction in a composite of recurrent coronary events among patients with diabetes, supporting secondary prevention. But this trial studied myocardial infarction survivors, not primary prevention, and the Results explicitly report no reduction in CHD death in the diabetes group. No page number is available in our copy. (LLM, conf=0.90)

  cites [103] Goldberg, 1998, Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators, Circulation sourceExperimental — accuracy not yet measured
• Partly supported

  The Efficacy outcomes section reports a significant reduction in major cardiovascular events among patients with diabetes and established CHD, supporting secondary prevention. It does not study primary prevention, and the reduction in CHD death in the diabetes subgroup was not statistically significant (P = 0.203). (LLM, conf=0.90)

  cites [104] Shepherd, 2006, Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study, Diabetes Care sourceExperimental — accuracy not yet measured
• Partly supported

  The ASCOT-LLA results (Statistical methods; page unavailable) report a significant reduction in total cardiovascular events and procedures among participants with diabetes, including those without preexisting cardiovascular disease. But the reduction in the diabetic subgroup for the endpoint combining fatal CHD and nonfatal myocardial infarction was not statistically significant. The paper reports benefits in an earlier trial among diabetic patients both with and without established cardiovascular disease, but its own results do not establish significant secondary prevention or a reduction in CHD death. (LLM, conf=0.89)

  cites [105] Sever, 2005, Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA), Diabetes Care sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [106] Knopp, 2006, Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN), Diabetes Care source
• ?Not checked — no full text of the sourcecites [107] Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet source

In the paper

“Multiple clinical trials have demonstrated the beneficial effects of statin therapy on ASCVD outcomes in subjects with and without coronary heart disease (CHD) (99,100).”

What the sources say

• Supported

  The Results report reduced major vascular-event risk with statins across 27 trials, including participants with and without previous vascular disease. The paper defines these events to include coronary events, strokes, and coronary revascularisations; its trial list includes studies in patients with CHD. (LLM, conf=0.90)

  cites [99] Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet source
• ?Not checked — no full text of the sourcecites [100] Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet source

In the paper

“Monitoring lipid profiles after initiation of statin therapy and during therapy increases the likelihood of dose titration and following the statin treatment plan (94)(95)(96).”

What the sources say

• ?Not checked — no full text of the sourcecites [94] Jia, 2019, Association between lipid testing and statin adherence in the Veterans Affairs health system, Am J Med source
• Partly supported

  The Results report that LDL-C testing after an ASCVD event was associated with higher statin adherence and treatment intensification. However, the claim generalizes this finding to lipid-profile monitoring during statin therapy more broadly and implies that monitoring increases these outcomes. The Discussion states that the observational design cannot establish a causal relationship. (LLM, conf=0.88)

  cites [95] Rana, 2022, Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification, Am J Med sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [96] Tran, 2022, Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center, J Clin Lipidol source

In the paper

“MRAs, including spironolactone and eplerenone, are effective for management of resistant hypertension in people with type 2 diabetes when added to existing treatment with an ACE inhibitor or ARB, thiazide-like diuretic, or dihydropyridine calcium channel blocker (88).”

What the sources say

• Partly supported

  The Introduction and Methods (pages not specified in our copy) describe spironolactone as an effective add-on for resistant hypertension in patients already taking an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic. The Discussion says almost 14% of participants had type 2 diabetes, but the cited passages do not establish efficacy specifically in that subgroup. PATHWAY-2 did not test eplerenone, so its effectiveness is not supported by this trial. (LLM, conf=0.88)

  cites [88] Williams, 2015, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial, Lancet sourceExperimental — accuracy not yet measured

In the paper

“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9, has demonstrated the ability to reduce LDL cholesterol by 49-52% in trials evaluating individuals with established cardiovascular disease or ASCVD risk equivalent (129).”

What the sources say

• Supported

  The Discussion (p. 9) reports placebo-adjusted LDL cholesterol reductions of 49.9% to 52.2% at month 17, consistent with the claim’s rounded range. The Methods (p. 1) identify the trial populations as patients with atherosclerotic cardiovascular disease or an ASCVD risk equivalent. (LLM, conf=0.93)

  cites [129] Ray, 2020, Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol, N Engl J Med source

In the paper

“In addition, MRAs reduce albuminuria in people with diabetic nephropathy (89)(90)(91).”

What the sources say

• Partly supported

  The Results section reports significantly reduced urinary albumin excretion after spironolactone was added to ACE-inhibitor treatment. The finding was in 13 patients with diabetic nephropathy and aldosterone escape, so it does not establish the unqualified claim for MRAs generally or for people with diabetic nephropathy outside that subgroup. (LLM, conf=0.86)

  cites [89] Sato, 2003, Effectiveness of aldosterone blockade in patients with diabetic nephropathy, Hypertension sourceExperimental — accuracy not yet measured
• Supported

  The Abstract reports that spironolactone, a mineralocorticoid receptor antagonist, reduced urine albumin-to-creatinine ratio compared with placebo in patients with diabetes, hypertension, and albuminuria. The finding is for spironolactone added to maximal-dose lisinopril, rather than for every MRA regimen. (LLM, conf=0.91)

  cites [90] Mehdi, 2009, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy, J Am Soc Nephrol source
• ?Not checked — no full text of the sourcecites [91] Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial, JAMA source

In the paper

“Lifestyle intervention, including weight loss in people with overweight or obesity (when appropriate) (19,92), increased physical activity, and medical nutrition therapy, allows some individuals to reduce ASCVD risk factors.”

What the sources say

• Supported

  The guideline’s section 4.1 (Adults With Overweight and Obesity) states that clinically meaningful weight loss improves blood pressure, LDL cholesterol, triglycerides, and glucose levels. Its nutrition and physical-activity sections also recommend dietary changes and increased activity to reduce ASCVD risk or risk factors. The citation is placed immediately after the weight-loss phrase, which section 4.1 directly supports. (LLM, conf=0.91)

  cites [19] Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation source
• Supported

  The weight-management Synopsis says that weight loss with lifestyle modification improves metabolic and hemodynamic risk profiles in patients with chronic coronary disease who have overweight or obesity. The nutrition section (p. e30) says healthy dietary choices improve cardiovascular risk-factor management, and the physical-activity Synopsis describes improved metabolic and cardiovascular health with increased activity. Together, these support the claim that such interventions can reduce risk factors in some individuals. (LLM, conf=0.90)

  cites [92] Virani, 2023, 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines, Circulation source

In the paper

“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (99).”

What the sources say

• Supported

  The Results report that the trials comparing more- versus less-intensive statin therapy were conducted solely in patients with previous coronary disease. The Discussion states that more intensive regimens further reduced major vascular events. The paper uses “more versus less intensive,” rather than the citing sentence’s “high-intensity versus moderate-intensity,” but supports the comparison and outcome attributed to it. (LLM, conf=0.88)

  cites [99] Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet source

In the paper

“The absolute risk increase was small (over 5 years of follow-up, 1.2% of participants on placebo developed diabetes and 1.5% on rosuvastatin developed diabetes) (164).”

What the sources say

• Partly supported

  The Results report more diabetes diagnoses with rosuvastatin than placebo (270 versus 216), supporting the direction of the increase. They do not report the claimed 1.5% and 1.2% participant risks. The Methods describe follow-up of up to five years, not five years for every participant. (LLM, conf=0.88)

  cites [164] Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet sourceExperimental — accuracy not yet measured

In the paper

“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (160)”

What the sources say

• Supported

  The Primary and Secondary End Points section reports more ischemic strokes in the niacin group than in the placebo group, but the difference was not statistically significant. The Discussion says a causal association is uncertain. The supplied passages do not give page numbers. (LLM, conf=0.93)

  cites [160] Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med source

In the paper

“As an example, the addition of 4 g per day of a carboxylic acid formulation of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (n-3 carboxylic acid) to statin therapy in individuals with atherogenic dyslipidemia and high cardiovascular risk, 70% of whom had diabetes, did not reduce the risk of major adverse cardiovascular events compared with the inert comparator of”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [154] Nicholls, 2020, Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial, JAMA source

In the paper

“The Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid or Placebo (CLEAR Outcomes) trial found a reduction in four-point major adverse cardiovascular events by 13% compared with placebo for individuals with established ASCVD (70% of population) or at high risk for ASCVD (30% of population) a”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [141] Nissen, 2023, Bempedoic acid and cardiovascular outcomes in statin-intolerant patients, N Engl J Med source

In the paper

“Prespecified subgroup analyses suggested heterogeneity in treatment effects with possible benefit for men with both a triglyceride level $204 mg/dL ($2.3 mmol/L) and an HDL cholesterol level #34 mg/dL (#0.9 mmol/L) (159).”

What the sources say

• Partly supported

  The Results (Clinical Outcomes; page unavailable) report separate subgroup findings: apparent benefit for men and a nonsignificant suggestion of benefit for patients with triglycerides ≥204 mg/dL and HDL cholesterol ≤34 mg/dL. The Discussion says the sex-by-treatment interaction was not observed within the dyslipidemia subgroup. The paper therefore does not establish the claimed combined subgroup of men meeting both lipid thresholds. (LLM, conf=0.88)

  cites [159] Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (166-169).”

What the sources say

• ?Not checked — no full text of the sourcecites [166] Heart Protection Study Collaborative Group., 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet source
• ?Not checked — no full text of the sourcecites [167] Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet source
• ?Not checked — no full text of the sourcecites [168] Trompet, 2010, Pravastatin and cognitive function in the elderly. Results of the PROSPER study, J Neurol source
• Partly supported

  The Methods (p. 1) identify a large randomized comparison of rosuvastatin with placebo. The available Results (p. 1) report cardiovascular outcomes and other adverse events, but do not report specific cognitive tests or a comparison of cognitive results between groups (searched: cognitive, memory, dementia, neuropsychological tests). The paper therefore supports the trial description, not the cognitive-outcome claim. (LLM, conf=0.83)

  cites [169] Yusuf, 2016, Cholesterol lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“Although concerns regarding a potential adverse impact of lipid-lowering agents on cognitive function have been raised, several lines of evidence argue against this association, as detailed in a 2018 European Atherosclerosis Society Consensus Panel statement (165).”

What the sources say

• Supported

  The Cognitive function section (p. 10) reports that a meta-analysis of 25 randomized trials found no significant negative effect of statins on cognitive function. The Take home messages (p. 10) also report no adverse cognitive signal at very low LDL-C levels attained with statins combined with ezetimibe or a PCSK9 inhibitor. These are several lines of evidence supporting the citing sentence's summary. (LLM, conf=0.91)

  cites [165] Mach, 2018, Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract, Eur Heart J source

In the paper

“In the ACCORD study, in people with type 2 diabetes who were at high risk for ASCVD, the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal MI, or nonfatal stroke compared with simvastatin alone.”

What the sources say

• Supported

  The Abstract (Methods) defines the primary outcome as nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in patients with type 2 diabetes receiving simvastatin plus fenofibrate or placebo. The Results (Clinical Outcomes; page unavailable) report no significant reduction in that outcome with fenofibrate (2.2% versus 2.4% annually; P=0.32), consistent with the claim. (LLM, conf=0.93)

  cites [159] Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med source

In the paper

“For individuals requiring primary prevention, the use of bempedoic acid resulted in a 30% reduction in primary composite outcome compared with placebo (143).”

What the sources say

• Supported

  The Clinical End Points section reports a hazard ratio of 0.70 for the primary composite outcome with bempedoic acid versus placebo, corresponding to a 30% relative reduction. The finding applies to the study’s high-risk, statin-intolerant primary prevention subgroup. (LLM, conf=0.92)

  cites [143] Nissen, 2023, Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients, JAMA source

In the paper

“Prespecified subanalyses evaluated the impact for individuals with diabetes and showed a 17% reduction in four-point major adverse cardiovascular events when treated with bempedoic acid (142).”

What the sources say

• Supported

  The paper describes this as a prespecified analysis in the Introduction. The Discussion (Figure 2A; page not provided) reports a MACE-4 hazard ratio of 0.83 for patients with diabetes treated with bempedoic acid, equivalent to a 17% relative risk reduction. (LLM, conf=0.95)

  cites [142] Ray, 2024, Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial, Lancet Diabetes Endocrinol source

In the paper

“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”

What the sources say

• Supported

  The secondary-prevention discussion reports that aspirin reduced serious vascular events, stroke, coronary events, and total mortality in people with prior myocardial infarction, stroke, or peripheral artery disease. The recommendations give a strong recommendation for aspirin after myocardial infarction and for an aspirin-containing regimen after non-cardioembolic stroke; aspirin alone is recommended after stroke when the preferred alternatives are not tolerated. (LLM, conf=0.90)

  cites [174] Perk, 2012, European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J source

In the paper

“In addition, systematic reviews of randomized controlled trials and prospective cohort studies evaluating cognition in individuals receiving statins found that published data do not reveal an adverse effect of statins on cognition (171,172).”

What the sources say

• Partly supported

  The Introduction says short-term evidence suggests no adverse cognitive effect, and the Discussion reports no increased cognitive decline in the trials it describes. But the Studies selection section says this review included observational cohort and case-control studies of Alzheimer’s disease or dementia risk—not a systematic review of randomized trials evaluating cognition generally. (LLM, conf=0.86)

  cites [171] Olmastroni, 2022, Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies, Eur J Prev Cardiol sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [172] Richardson, 2013, Statins and cognitive function: a systematic review, Ann Intern Med source

In the paper

“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (119) or PCSK9 inhibitors (121,170) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”

What the sources say

• ?Could not verify

  The Lipid Data section reports that ezetimibe added to simvastatin lowered LDL cholesterol to a mean of 53.2 mg/dl at one year. The Discussion reports no significant differences in prespecified safety endpoints, but neither section reports a cognitive-function assessment or result. A search for cognition, memory, and neurocognitive outcomes found no passage supporting the claim attributed to this ezetimibe study. (LLM, conf=0.76)

  cites [119] Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Results report no significant difference in neurocognitive adverse events between evolocumab and placebo, and the Lipid Data section shows that many evolocumab-treated patients reached very low LDL cholesterol levels. The paper does not report cognitive-function testing or establish the absence of cognitive changes specifically among patients who reached those levels. The ezetimibe finding has a separate citation in the citing sentence and is not attributed to this paper. (LLM, conf=0.83)

  cites [121] Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med sourceExperimental — accuracy not yet measured
• Supported

  The Conclusions report no significant difference in cognitive function between patients receiving evolocumab or placebo in addition to statin therapy over a median of 19 months. The Discussion adds that this finding held even among patients who attained very low LDL cholesterol levels. The ezetimibe portion of the citing sentence is assigned to a different citation. (LLM, conf=0.93)

  cites [170] Giugliano, 2017, Cognitive function in a randomized trial of evolocumab, N Engl J Med source

In the paper

“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”

What the sources say

• Partly supported

  The Discussion reports that AIM-HIGH found no incremental cardiovascular benefit from adding niacin to intensive statin therapy in its studied patients. It describes HPS2-THRIVE as still in follow-up, so this paper does not support the claim that HPS2-THRIVE had also failed to demonstrate a benefit. (LLM, conf=0.91)

  cites [160] Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [161] Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med source

In the paper

“Use of this agent with ezetimibe results in an additional 19% reduction in LDL cholesterol (140).”

What the sources say

• Supported

  The Results report that, across four studies, adding bempedoic acid to ezetimibe background therapy was associated with a mean additional LDL-C reduction of 19.03% (95% CI −22.67% to −15.39%). This supports the cited 19% figure. (LLM, conf=0.94)

  cites [140] De Filippo, 2023, Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials, Cardiovasc Diabetol source

In the paper

“In ASPREE, which included 19,114 individuals, for cardiovascular disease (fatal CHD, MI, stroke, or hospitalization for heart failure) after a median of 4.7 years of follow-up, the rates per 1,000 person-years were 10.7 vs. 11.3 events in aspirin vs. placebo groups (HR 0.95 [95% CI 0.83-1.08]).”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [181] McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med source

In the paper

“In ARRIVE, with 12,546 individuals over a period of 60 months of follow-up, the primary end point occurred in 4.29% vs. 4.48% of individuals in the aspirin versus placebo groups (HR 0.96 [95% CI 0.81-1.13];P = 0.60).”

What the sources say

• Supported

  The Results report primary-endpoint rates of 4.29% with aspirin and 4.48% with placebo, with HR 0.96 (95% CI 0.81–1.13) and p=0.6038, which rounds to 0.60. The Results also report 12,546 participants and a median follow-up of 60 months. (LLM, conf=0.95)

  cites [180] Gaziano, 2018, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, Lancet source

In the paper

“However, an increased risk of major bleeding was noted with rivaroxaban added to aspirin treatment in both COMPASS and VOYAGER PAD.”

What the sources say

• Partly supported

  The Results section reports a significant increase in major bleeding with rivaroxaban plus aspirin in the COMPASS analysis. Our copy does not report a major-bleeding result for VOYAGER PAD, so it supports only the COMPASS part of the claim. (LLM, conf=0.88)

  cites [205] Bhatt, 2020, Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial, Circulation sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [206] Connolly, 2018, Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial, Lancet source
• Partly supported

  The Abstract and Discussion report significantly more ISTH major bleeding with rivaroxaban plus aspirin in VOYAGER PAD, but no significant difference in the trial’s principal TIMI major-bleeding outcome. The paper discusses COMPASS’s reduction in ischemic risk but does not report a COMPASS major-bleeding finding, so it supports only the VOYAGER PAD portion of the claim. (LLM, conf=0.88)

  cites [207] Bonaca, 2020, Rivaroxaban in peripheral artery disease after revascularization, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“In the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness) trial of individuals with established cardiovascular disease, 38% of whom had diabetes, there were no significant differences in cardiovascular events or major bleeding between individuals assigned to 81 mg and those assigned to 325 mg of aspirin daily (191).”

What the sources say

• Supported

  The Abstract Conclusions state that patients with established cardiovascular disease assigned to 81 mg or 325 mg of aspirin daily had no significant differences in cardiovascular events or major bleeding. The Abstract Results report the event rates and hazard ratios for both outcomes. The Discussion notes substantial switching from the 325-mg dose, which qualifies interpretation of the trial results but does not change the reported comparison between assigned groups. (LLM, conf=0.94)

  cites [191] Jones, 2021, Comparative effectiveness of aspirin dosing in cardiovascular disease, N Engl J Med source

In the paper

“Gastrointestinal bleeding events (characterized as mild) occurred in 0.97% of individuals in the aspirin group vs. 0.46% in the placebo group (HR 2.11 [95% ; P = 0.0007).”

What the sources say

• Supported

  The Results report gastrointestinal bleeding in 61 aspirin recipients (0.97%) versus 29 placebo recipients (0.46%), with HR 2.11 and p=0.0007. The same passage says the events were predominantly mild. (LLM, conf=0.95)

  cites [180] Gaziano, 2018, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, Lancet source

In the paper

“Overall, they found that aspirin reduced the risk of serious vascular events by 12% (relative risk 0.88 [95% CI 0.82-0.94]).”

What the sources say

• Supported

  The Results (passage 2; page not supplied) report a 12% reduction in serious vascular events in the primary prevention trials, with RR 0.88 (95% CI 0.82–0.94). The Results (passage 8) identify six primary prevention trials. The paper describes their participants as low average risk, rather than explicitly calling them the general population. (LLM, conf=0.95)

  cites [178] Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet source

In the paper

“The absolute benefits of combination therapy appeared larger in people with diabetes, who comprised 10,341 of the trial participants (205,206).”

What the sources say

• Supported

  The Results report that absolute risk reductions with rivaroxaban plus aspirin appeared larger in patients with diabetes than in those without it. The Results also state that 10,341 of the 27,395 COMPASS participants had diabetes at enrollment; 6,922 of those with diabetes were in the two treatment arms analyzed here. (LLM, conf=0.94)

  cites [205] Bhatt, 2020, Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial, Circulation source
• ?Not checked — no full text of the sourcecites [206] Connolly, 2018, Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial, Lancet source

In the paper

“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”

What the sources say

• Partly supported

  The Conclusions (p. 1) say that, among participants with diabetes and no evident cardiovascular disease, aspirin’s benefits were largely counterbalanced by bleeding—not that risk exceeded benefit. The Participants section (p. 3) confirms the trial included only people with diabetes, and the cited passages do not establish the claimed balance specifically for people over 70 or for those without diabetes. (LLM, conf=0.87)

  cites [179] Bowman, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Abstract Conclusions report that, for primary prevention in older adults, aspirin increased major hemorrhage without significantly reducing cardiovascular disease. The Methods and Results include diabetes as a subgroup and report no evidence of a differential cardiovascular effect. The claim omits the trial’s important limitation to generally healthy people without established cardiovascular disease; it should not be extended to everyone over 70. (LLM, conf=0.85)

  cites [181] McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“Rivaroxaban treatment in this group of individuals was also associated with a significantly lower incidence of ischemic cardiovascular events, including major adverse limb events.”

What the sources say

• Supported

  The Abstract reports that, after lower-extremity revascularization, rivaroxaban 2.5 mg twice daily plus aspirin significantly reduced the primary composite outcome compared with placebo plus aspirin (P = 0.009). That outcome included acute limb ischemia and major amputation for vascular causes, as well as cardiovascular events. (LLM, conf=0.93)

  cites [207] Bonaca, 2020, Rivaroxaban in peripheral artery disease after revascularization, N Engl J Med source

In the paper

“In the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial of 27,395 individuals with established coronary artery disease and/or PAD, aspirin plus rivaroxaban 2.5 mg twice daily was superior to aspirin plus placebo in the reduction of cardiovascular ischemic events, including major adverse limb events.”

What the sources say

• Supported

  The Methods describe COMPASS as a trial of 27,395 patients with coronary or peripheral artery disease randomized to the stated regimens. The Results report a significant reduction with rivaroxaban plus aspirin in the expanded ischemic-event outcome, which included major adverse limb events. The paper does not establish a separate reduction in limb events alone, but the claim presents them as part of the combined outcome. (LLM, conf=0.93)

  cites [205] Bhatt, 2020, Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial, Circulation source
• ?Not checked — no full text of the sourcecites [206] Connolly, 2018, Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial, Lancet source

In the paper

“Combination dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is indicated after acute coronary syndromes and coronary revascularization with stenting (197).”

What the sources say

• Supported

  The Introduction defines DAPT as aspirin plus a P2Y12 receptor inhibitor. The Recommendations for Duration of DAPT in Patients With ACS Treated With PCI state that patients with ACS after bare-metal or drug-eluting stent implantation should receive P2Y12 inhibitor therapy for at least 12 months. The guideline also supports DAPT after ACS without stenting. Page numbers were not provided for these passages. (LLM, conf=0.94)

  cites [197] Levine, 2016, 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardia source

In the paper

“The rate of major hemorrhage per 1,000 person-years was 8.6 events versus 6.2 events, respectively (HR 1.38 [95% CI 1.18-1.62];P < 0.001).”

What the sources say

• Supported

  The Results section (“Major Hemorrhagic Events”) reports 8.6 major hemorrhages per 1,000 person-years in the aspirin group versus 6.2 in the placebo group, with the stated hazard ratio, confidence interval, and P value. (LLM, conf=0.95)

  cites [181] McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med source

In the paper

“For people with documented ASCVD, use of aspirin for secondary prevention has far greater benefit than risk; for this indication, aspirin is still recommended (174).”

What the sources say

• Supported

  The passage on long-term secondary prevention after myocardial infarction, stroke, or peripheral arterial disease says aspirin’s benefits exceeded its bleeding hazards. The recommendation table also recommends aspirin for secondary prevention in the chronic phase after myocardial infarction, although it lists other preferred options for some stroke patients. (LLM, conf=0.91)

  cites [174] Perk, 2012, European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J source

In the paper

“During a mean follow-up of 7.4 years, there was a significant 12% reduction in the primary efficacy end point (8.5% vs. 9.6%; P = 0.01).”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [179] Bowman, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med source

In the paper

“However, early aspirin discontinuation compared with continued dual antiplatelet therapy after coronary stenting may reduce the risk of bleeding without a corresponding increase in the risks of mortality and ischemic events, as shown in a prespecified analysis of people with diabetes enrolled in the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) trial”

What the sources say

• ?Not checked — no full text of the sourcecites [203] Angiolillo, 2020, Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention, J Am Coll Cardiol source
• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [204] Wiebe, 2021, Early aspirin discontinuation after coronary stenting: a systematic review and meta-analysis, J Am Heart Assoc source

In the paper

“In addition, the presence of microvascular disease is associated with adverse outcomes in people with PAD, including an increased risk for future limb amputation (239,240).”

What the sources say

• Supported

  The Results (Amputation) report incident amputations over a median 9.3 years of follow-up and a higher adjusted amputation risk with both PAD and microvascular disease than with PAD alone. The Discussion describes microvascular disease as adding to PAD-related adverse limb outcomes. (LLM, conf=0.93)

  cites [239] Beckman, 2019, Microvascular disease, peripheral artery disease, and amputation, Circulation source
• ?Not checked — no full text of the sourcecites [240] Olesen, 2022, Microvascular disease increases the risk of lower limb amputation - a Western Danish cohort study, Eur J Clin Invest source

In the paper

“A randomized observational trial demonstrated no clinical benefit of routine screening with adenosine-stress radionuclide myocardial perfusion imaging in asymptomatic people with type 2 diabetes and normal ECGs (210).”

What the sources say

• Partly supported

  The Abstract and Comment describe a randomized controlled trial and report that MPI screening did not significantly reduce cardiac events in asymptomatic patients with type 2 diabetes. The Methods excluded specified abnormal resting ECG findings, but did not require an entirely normal ECG. The claim's description of an observational trial and its unqualified 'normal ECGs' are therefore inaccurate. (LLM, conf=0.86)

  cites [210] Young, 2009, Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial, JAMA sourceExperimental — accuracy not yet measured

In the paper

“ACE inhibitors or ARB therapy also have well-established long-term benefit in people with diabetes and CKD or hypertension, and these agents are recommended for hypertension management in people with known ASCVD (particularly coronary artery disease) (72,73,246).”

What the sources say

• Partly supported

  The Blood Pressure Control section recommends ACE inhibitors or ARBs for hypertension in patients with type 2 diabetes and coronary artery disease, and reports reduced kidney-disease progression in patients with albuminuria. It also describes cardiovascular benefit over 4.5 years. The claim extends these benefits to people with diabetes and CKD or hypertension generally, without the source’s albuminuria and coronary-disease qualifications. (LLM, conf=0.84)

  cites [72] Arnold, 2020, Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association, Circulation sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [73] Yusuf, 2008, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial, Lancet source
• ?Not checked — no full text of the sourcecites [246] Braunwald, 2004, Angiotensin-converting-enzyme inhibition in stable coronary artery disease, N Engl J Med source

In the paper

“While a positive screening test for PAD in an asymptomatic population has been associated with increased cardiovascular event rates (241,242), prospective, randomized studies addressing whether screening for PAD in people with diabetes improves longterm limb outcomes and cardiovascular event rates are limited.”

What the sources say

• Partly supported

  The Results report higher 1-year major adverse cardiovascular event rates after a positive PAD screen than after a negative screen (5.54% versus 3.60%). The Discussion describes participants as previously unknown to have PAD, but does not establish that the screened population was asymptomatic; that qualifier is not supported. (LLM, conf=0.84)

  cites [241] Smolderen, 2022, Peripheral artery disease screening in the community and 1-year mortality, cardiovascular events, and adverse limb events, AJPM Focus sourceExperimental — accuracy not yet measured
• Supported

  The Conclusions describe the screened PAD as asymptomatic, and the Results report higher major adverse cardiovascular event (MACE) rates after a positive rather than negative screen. The finding concerns Medicare Advantage beneficiaries aged 65 or older; the adjusted association was significant at three years, but not at one year. (LLM, conf=0.92)

  cites [242] Smolderen, 2022, The Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk, J Vasc Surg source

In the paper

“Identification, risk stratification, and early treatment of risk factors in people with diabetes and asymptomatic stages of heart failure reduce the risk for progression to symptomatic heart failure (221,222).”

What the sources say

• ?Not checked — no full text of the sourcecites [221] Ledwidge, 2013, Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial, JAMA source
• Partly supported

  The Abstract reports fewer cardiac events after NT-proBNP-guided treatment in patients with type 2 diabetes who were free of cardiac disease. The Conclusions table also shows fewer heart-failure hospitalizations in the intensified group (1 versus 7), but the study did not establish that participants had asymptomatic heart failure or directly measure progression to symptomatic heart failure. The claim extends the findings beyond the population and outcome studied. (LLM, conf=0.86)

  cites [222] Huelsmann, 2013, PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol sourceExperimental — accuracy not yet measured

In the paper

“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (222,227,228).”

What the sources say

• Partly supported

  The Study design and hospitalization tables (pp. 1365–72; precise page unavailable in our copy) describe a randomized trial in patients with type 2 diabetes and elevated NT-proBNP. They report fewer heart-failure hospitalizations with intensified treatment (1 versus 7), although the reported time-to-event comparison was not statistically significant (p=0.07). The paper does not report symptomatic heart failure or newly diagnosed left ventricular dysfunction as outcomes; it also represents one trial, not evidence of results from several trials by itself. (LLM, conf=0.87)

  cites [222] Huelsmann, 2013, PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
• Partly supported

  The Results (statistical analysis; page unavailable) report that intensive multifactorial treatment reduced a composite cardiovascular outcome in one trial of patients with type 2 diabetes and microalbuminuria. The paper does not report selecting patients by elevated natriuretic peptides or reductions in symptomatic heart failure, heart-failure hospitalization, or newly diagnosed left ventricular dysfunction; it also does not itself establish a finding from several trials. (LLM, conf=0.82)

  cites [227] Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [228] Gaede, 2005, Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“People with diabetes are at an increased risk for developing heart failure, as shown in multiple longitudinal, observational studies (216,217).”

What the sources say

• Supported

  The Discussion reports an elevated risk of heart-failure hospitalization in people with diabetes in both this study and the REACH registry, and describes a separate population-based study with a similar finding. The Conclusion states that heart-failure incidence remains approximately twice as high in people with diabetes as in those without it. Page numbers are not provided in our copy. (LLM, conf=0.92)

  cites [216] McAllister, 2018, Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus, Circulation source
• Supported

  The Methods section states that the review included observational cohort studies, and the Results section reports data from 47 cohorts. Its pooled estimates show a higher risk of heart failure in people with type 1 or type 2 diabetes than in those without diabetes. Page numbers were not available in our copy. (LLM, conf=0.94)

  cites [217] Ohkuma, 2019, Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals, Diabetologia source

In the paper

“Studies have also found that a risk factor-based approach to the initial diagnostic evaluation and subsequent follow-up for coronary artery disease fails to identify which people with type 2 diabetes will have silent ischemia on screening tests (212,213).”

What the sources say

• Partly supported

  The Clinical implications section (p. 6) says the two-or-more-risk-factor screening recommendation did not accurately identify many patients with abnormal tests, supporting the claim about initial screening. It also says the study addressed silent ischemia only at enrollment and that five-year follow-up results were still forthcoming; it does not support the claim about subsequent follow-up. (LLM, conf=0.88)

  cites [212] Wackers, 2004, Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study, Diabetes Care sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion (page not supplied) reports that risk factors did not significantly predict myocardial perfusion abnormalities in asymptomatic patients with type 2 diabetes, supporting the claim about initial screening. It does not establish that a risk factor-based approach fails during subsequent follow-up; the Discussion says the study’s five-year follow-up was still pending. (LLM, conf=0.86)

  cites [213] Scognamiglio, 2006, Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus, J Am Coll Cardiol sourceExperimental — accuracy not yet measured

In the paper

“Conversely, up to twothirds of people with asymptomatic PAD have been shown to have comorbid diabetes (236).”

What the sources say

• Supported

  The Results (Table 1) report that 16 of 25 patients with asymptomatic PAD had diabetes (64%), approximately two-thirds. This supports the citing sentence’s claim that such a proportion has been observed. (LLM, conf=0.94)

  cites [236] Eason, 2005, Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: whom should we screen?, J Am Board Fam Pract source

In the paper

“In people with type 2 diabetes, measurement of natriuretic peptides, including B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP), identifies people at risk for heart failure development, progression of symptoms, and heart failure-related mortality (223-225).”

What the sources say

• Partly supported

  The Discussion reports that elevated NT-proBNP is associated with incident heart failure in people with type 2 diabetes, and the outcomes analysis finds baseline NT-proBNP prognostic for heart-failure hospitalization and the combined outcome of hospitalization or cardiovascular death. The paper does not establish the same findings for BNP measured separately, symptom progression, or heart-failure-related mortality specifically. (LLM, conf=0.86)

  cites [223] Januzzi, 2020, Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: implications for cardiovascular risk reduction, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [224] Jarolim, 2018, Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE trial, Diabetes Care source
• Partly supported

  The Methods include NT-proBNP in a composite biomarker score, and the Results report that the score stratified incident heart-failure risk among participants with diabetes. The paper does not establish the same predictive claim for BNP alone or address symptom progression or heart-failure-related mortality; its stated primary outcome was incident heart failure. The indexed passages provide section labels but no page numbers. (LLM, conf=0.88)

  cites [225] Pandey, 2021, Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes, JACC Heart Fail sourceExperimental — accuracy not yet measured

In the paper

“In a large multinational cohort of 750,000 people with diabetes without established cardiovascular disease, heart failure and CKD were the most frequent first manifestations of cardiovascular or kidney disease (218).”

What the sources say

• Supported

  The Results (First CVRD manifestation) report that 772,336 patients with type 2 diabetes were initially free of cardiovascular or renal disease. Heart failure and CKD together accounted for 60% of first manifestations, more than any of the other categories reported. (LLM, conf=0.94)

  cites [218] Birkeland, 2020, Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study, Diabetes Obes Metab source

In the paper

“People with diabetes are at particularly high risk for progression from asymptomatic stage A and B to symptomatic stage C and D heart failure (219,220).”

What the sources say

• Partly supported

  The Conclusions (p. 2) say heart failure is common among adults with type 2 diabetes, and the Results (p. 4) document incident heart-failure events in participants without prior heart failure. The paper does not classify participants by heart-failure stage or establish that people with diabetes are particularly likely, relative to others, to progress from stages A or B to C or D. (LLM, conf=0.86)

  cites [219] Segar, 2020, Association of long-term change and variability in glycemia with risk of incident heart failure among patients with type 2 diabetes: a secondary analysis of the ACCORD trial, Diabetes Care sourceExperimental — accuracy not yet measured
• Supported

  The Discussion reports that diabetes was associated with progression from preclinical stages A and B to symptomatic heart failure and increased risk in both stages. The Conclusion likewise reports substantial excess risk of progression to overt heart failure among participants with uncontrolled diabetes in stages A and B. (LLM, conf=0.92)

  cites [220] Echouffo-Tcheugui, 2022, Diabetes and progression of heart failure: The Atherosclerosis Risk In Communities (ARIC) study, J Am Coll Cardiol source

In the paper

“The risk for PAD in people with diabetes is higher than that in people without diabetes (230-232).”

What the sources say

• Supported

  The Prevalence of PAD section reports PAD in 10.8% of participants with diabetes versus 3.6% without diabetes. The Abstract also reports that diabetes was positively associated with prevalent PAD (age- and gender-adjusted OR 2.71). These findings support the comparative risk statement, though the study measured prevalent PAD rather than future incidence. (LLM, conf=0.94)

  cites [230] Selvin, 2004, Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000, Circulation source
• Supported

  The introduction (section U) states that individuals with diabetes were at significantly increased risk of developing PAD. The paper’s conclusion also identifies diabetes as a risk factor for PAD. (LLM, conf=0.93)

  cites [231] Leibson, 2004, Peripheral arterial disease, diabetes, and mortality, Diabetes Care source
• ?Not checked — no full text of the sourcecites [232] Murabito, 1997, Intermittent claudication. A risk profile from The Framingham Heart Study, Circulation source

In the paper

“However, lixisenatide and extended-release exenatide were not superior to placebo with respect to the primary end point of cardiovascular outcomes (265).”

What the sources say

• Supported

  The Discussion reports that once-weekly extended-release exenatide was not superior to placebo for cardiovascular efficacy. It also reports that the ELIXA trial found no significant difference between lixisenatide and placebo in a cardiovascular MACE outcome. Page numbers are not available in our copy. (LLM, conf=0.91)

  cites [265] Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“Of note, there was an increased risk of lower-limb amputation with canagliflozin ( 6.3 vs. 3.4 participants per 1,000 person-years; HR 1.97 [95% CI 1.41-2.75]) (256).”

What the sources say

• Supported

  The Safety Outcomes section reports a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo. It gives the same rates and hazard ratio with 95% confidence interval as the citing sentence. (LLM, conf=0.95)

  cites [256] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med source

In the paper

“but did not show a lower rate of major adverse cardiovascular events compared with placebo (8.8% in the dapagliflozin group and 9.4% in the placebo group; HR 0.93 [95% CI 0.84-1.03];P = 0.17) (258).”

What the sources say

• Supported

  The Results section reports that dapagliflozin did not result in a significantly lower rate of major adverse cardiovascular events than placebo. It gives the same event rates, hazard ratio, confidence interval, and P value as the citing sentence. (LLM, conf=0.95)

  cites [258] Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“Further studies have shown renoprotective effects of dapagliflozin (259).”

What the sources say

• Supported

  The Efficacy Outcomes section reports fewer kidney-related events with dapagliflozin than with placebo in participants with chronic kidney disease. The Discussion describes the trial's findings as kidney-protective, including in participants without type 2 diabetes. Page numbers are not specified in the supplied passages. (LLM, conf=0.94)

  cites [259] Heerspink, 2020, Dapagliflozin in patients with chronic kidney disease, N Engl J Med source

In the paper

“Subsequent retrospective analyses from both trials revealed that concomitant use of b-blockers was associated with decreased risk of progression to symptomatic heart failure (280,281).”

What the sources say

• Supported

  The Conclusions in the 'Differential effect in prevention trial' section state that progression to symptomatic heart failure was significantly reduced among SOLVD Prevention trial patients receiving both a beta-blocker and enalapril. This supports the SOLVD portion of the citing sentence; the separate SAVE analysis is not attributed to this source alone. (LLM, conf=0.91)

  cites [280] Exner, 1999, Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction, J Am Coll Cardiol source
• Partly supported

  The Results (section 2.2) and Discussion (section 3.1) report that beta-blocker use in the retrospective SAVE analysis was associated with a lower risk of developing severe heart failure. The Methods (section 1.2) define that endpoint as heart failure requiring hospitalization or clinical deterioration requiring open-label ACE inhibition; the paper does not establish a reduction in progression to symptomatic heart failure more generally. This source addresses SAVE, not SOLVD. (LLM, conf=0.84)

  cites [281] Vantrimpont, 1997, Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators, J Am Coll Cardiol sourceExperimental — accuracy not yet measured

In the paper

“Early primary prevention strategies and treatment of associated risk factors reduce incident, symptomatic heart failure and should include lifestyle intervention with nutrition, physical activity, weight management, and smoking cessation (271-274) (Fig. 10.6).”

What the sources say

• Partly supported

  The Conclusions (page not specified) report that physical activity, not smoking, and avoiding obesity were associated with lower incident heart-failure risk in older adults. The Methods define incident heart failure using symptoms and clinical findings, supporting the reference to symptomatic disease. But this observational study does not establish that early prevention strategies or treatment of associated risk factors reduce incidence. (LLM, conf=0.88)

  cites [271] Del Gobbo, 2015, Contribution of major lifestyle risk factors for incident heart failure in older adults: the Cardiovascular Health Study, JACC Heart Fail sourceExperimental — accuracy not yet measured
• Partly supported

  The Results (page not provided) report fewer incident heart-failure diagnoses among men with higher physical activity, supporting the physical-activity aspect of prevention. The Clinical Perspective (page not provided) describes this as an association and says whether changing these behaviors affects risk remains for future study. The paper does not establish that early prevention strategies or treatment of associated risk factors reduce symptomatic heart failure. (LLM, conf=0.86)

  cites [272] Young, 2014, Effects of physical activity and sedentary time on the risk of heart failure, Circ Heart Fail sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion (page not available) reports that greater adherence to a Mediterranean diet was associated with lower risk of developing heart failure in men. That supports the nutrition aspect of primary prevention, but this observational finding does not establish that interventions or treatment of risk factors reduce symptomatic heart failure. The paper does not report benefits from physical activity, weight management, or smoking cessation interventions. (LLM, conf=0.86)

  cites [273] Tektonidis, 2016, Adherence to a Mediterranean diet is associated with reduced risk of heart failure in men, Eur J Heart Fail sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction (page not provided) discusses preventing heart failure through treatment and lifestyle interventions targeting risk factors, and the Abstract Conclusions report lower heart-failure rates among people whose diets were consistent with DASH. But the study reports an association, not that early prevention or risk-factor treatment reduces incident symptomatic heart failure; it also did not assess when prevention began. (LLM, conf=0.85)

  cites [274] Levitan, 2009, Consistency with the DASH diet and incidence of heart failure, Arch Intern Med sourceExperimental — accuracy not yet measured

In the paper

“No difference was seen in cardiovascular death between groups.”

What the sources say

• Supported

  The Cardiovascular and Renal Outcomes section explicitly reports no difference in cardiovascular death between the dapagliflozin and placebo groups (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). The Discussion likewise says dapagliflozin did not produce a lower rate of cardiovascular death. (LLM, conf=0.95)

  cites [258] Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial was a randomized, double-blind trial that assessed the effect of liraglutide, a GLP-1 RA, versus placebo on cardiovascular outcomes in 9,340 people with type 2 diabetes at high risk for cardiovascular disease or with cardiovascular disease (261).”

What the sources say

• Supported

  The Methods describe LEADER as a randomized, double-blind, placebo-controlled trial comparing liraglutide with placebo in patients with type 2 diabetes at high cardiovascular risk. The Results report 9,340 randomized patients, including many with established cardiovascular disease. Page numbers are not provided in our copy. (LLM, conf=0.95)

  cites [261] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“Results of trials with semaglutide, albiglutide, and dulaglutide, once-weekly GLP-1 RAs, were consistent with the LEADER trial (262-264).”

What the sources say

• Supported

  The Discussion says that cardiovascular-outcome findings for GLP-1 receptor agonists were consistent and reports significant benefits in the LEADER, Harmony Outcomes, SUSTAIN-6, and REWIND trials. It identifies these as trials of liraglutide, albiglutide, subcutaneous semaglutide, and dulaglutide, respectively. (LLM, conf=0.89)

  cites [262] Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med source
• Supported

  The Discussion (page not specified in our copy) says the cardiovascular effects observed with once-weekly albiglutide were consistent with the benefits of liraglutide, the drug tested in LEADER. This source supports the albiglutide part of the sentence; the other citations accompany the semaglutide and dulaglutide trials. (LLM, conf=0.93)

  cites [263] Hernandez, 2018, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet source
• ?Not checked — no full text of the sourcecites [264] Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet source

In the paper

“in the UK Prospective Diabetes Study (UKPDS) trial, intensive blood pressure management in people with type 2 diabetes reduced the risk for heart failure by 56% (276).”

What the sources say

• Supported

  The Discussion reports a 56% reduction in heart-failure risk among patients with hypertension and type 2 diabetes assigned to tight blood-pressure control. The Introduction identifies this as a randomized trial embedded in the UK Prospective Diabetes Study. (LLM, conf=0.94)

  cites [276] UK Prospective Diabetes Study Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ source

In the paper

“which reflected a lower rate of hospitalization for heart failure (HR 0.73 [95% CI 0.61-0.88]).”

What the sources say

• Supported

  The Cardiovascular and Renal Outcomes section states that the lower rate of the composite outcome with dapagliflozin was due to fewer hospitalizations for heart failure, and gives the claimed hazard ratio and confidence interval. (LLM, conf=0.95)

  cites [258] Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit;”

What the sources say

• Partly supported

  The Discussion (p. 7) reports that efpeglenatide reduced cardiovascular and renal events in high-risk patients with type 2 diabetes, and suggests those benefits occurred independently of baseline SGLT2 inhibitor use. This supports a possible benefit from combining the drugs, but the trial did not establish an additive cardiovascular and kidney benefit for the two drug classes generally. (LLM, conf=0.82)

  cites [270] Gerstein, 2021, Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“Meta-analyses of the trials reported to date suggest that GLP-1 RAs and SGLT2 inhibitors reduce risk of atherosclerotic major adverse cardiovascular events to a comparable degree in people with type 2 diabetes and established ASCVD (266,267).”

What the sources say

• ?Not checked — no full text of the sourcecites [266] Zelniker, 2019, Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus, Circulation source
• Partly supported

  The Results > Outcomes section reports that both drug classes reduced non-fatal myocardial infarction, with no detected difference between them. It also reports that GLP-1 receptor agonists reduced non-fatal stroke whereas SGLT-2 inhibitors had little or no effect. The paper does not establish comparable reductions in composite atherosclerotic major adverse cardiovascular events specifically among people with established ASCVD. (LLM, conf=0.87)

  cites [267] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured

In the paper

“Similarly, in the SPRINT trial, intensive treatment of hypertension decreased the risk for development of incident heart failure by 36% (277).”

What the sources say

• Partly supported

  The Conclusions report a 36% reduction in acute decompensated heart failure (ADHF) with intensive blood-pressure treatment in SPRINT. The Methods (Study Outcomes) say all ADHF events were incident heart-failure events, but define them as events requiring hospital or emergency-department treatment. The claim broadens that specific outcome to incident heart failure generally. (LLM, conf=0.86)

  cites [277] Upadhya, 2017, Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial, Circ Heart Fail sourceExperimental — accuracy not yet measured

In the paper

“A lower rate of cardiovascular death or hospitalization for heart failure was noted (4.9% vs. 5.8%; HR 0.83 [95% CI 0.73-0.95];P = 0.005)”

What the sources say

• Supported

  The Cardiovascular and Renal Outcomes section reports a lower rate of cardiovascular death or hospitalization for heart failure with dapagliflozin than with placebo, with exactly the cited rates, hazard ratio, confidence interval, and P value. The result concerns the composite outcome; the paper notes that the difference reflected fewer hospitalizations for heart failure, not fewer cardiovascular deaths. (LLM, conf=0.95)

  cites [258] Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“Deaths from cardiovascular causes were significantly reduced in the liraglutide group (4.7%) compared with the placebo group (6.0%) (HR 0.78 [95% CI 0.66-0.93];P = 0.007) (261).”

What the sources say

• Supported

  The Abstract Results report cardiovascular deaths in 4.7% of the liraglutide group versus 6.0% of the placebo group, with a hazard ratio of 0.78 (95% CI, 0.66–0.93; P=0.007). The Methods identify this as the LEADER trial in patients with type 2 diabetes and high cardiovascular risk. (LLM, conf=0.95)

  cites [261] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“The Dapagliflozin Effect on Cardiovascular Events-Thrombosis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial met the prespecified criteria for noninferiority to placebo with respect to major adverse cardiovascular events”

What the sources say

• Supported

  The RESULTS section states that dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE in DECLARE-TIMI 58. The Discussion likewise identifies MACE as the trial’s primary safety outcome. (LLM, conf=0.95)

  cites [258] Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“Similarly, canagliflozin significantly reduced the composite outcome of cardiovascular death, MI, or stroke versus placebo (occurring in 26.9 vs. 31.5participants per 1,000 person-years; HR 0.86 [95% CI 0.75-0.97]).”

What the sources say

• Supported

  The Cardiovascular Outcomes, Death, and Hospitalizations section reports significantly fewer primary-outcome events with canagliflozin than placebo. It defines the composite as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke and gives the cited rates, hazard ratio, and confidence interval. (LLM, conf=0.95)

  cites [256] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med source

In the paper

“In the EMPA-REG OUTCOME trial, only 10% of study participants had a prior history of heart failure, and treatment with empagliflozin reduced the relative risk for hospitalization from heart failure by 35% (255).”

• Also stated in: § GLP-1 Receptor Agonist Trials · boosted

  “Briefly, in the EMPA-REG OUTCOME trial, the addition of empagliflozin to standard care led to a significant 35% reduction in hospitalization for heart failure compared with placebo (255).”

What the sources say

• Supported

  The Results (p. 1) explicitly report a 35% relative risk reduction in hospitalization for heart failure with empagliflozin versus placebo. The Cardiovascular Outcomes section (p. 4) reports the corresponding hazard ratio of 0.65. (LLM, conf=0.95)

  cites [255] Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med source

In the paper

“Similarly, in CANVAS and DECLARE-TIMI 58, there were 33% and 27% reductions, respectively, in hospitalization for heart failure with SGLT2 inhibitor use versus placebo (256,258).”

What the sources say

• Supported

  Figure 2 in the paper’s Discussion lists a hazard ratio of 0.73 (95% CI, 0.61–0.88) for hospitalization for heart failure with dapagliflozin versus placebo. That corresponds to a 27% relative reduction in DECLARE-TIMI 58. (LLM, conf=0.94)

  cites [258] Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med source

In the paper

“Additional data from the CREDENCE trial with canagliflozin showed a 39% reduction in hospitalization for heart failure and a 31% reduction in the composite of cardiovascular death or hospitalization for heart failure, in a population with CKD and albuminuria (UACR >300-5,000 mg/g) (257).”

What the sources say

• Supported

  The Secondary and Exploratory Outcomes section (page not available in our copy) reports a hazard ratio of 0.69 for cardiovascular death or hospitalization for heart failure, equivalent to a 31% lower relative risk with canagliflozin. The Methods section identifies the trial population as having albuminuric chronic kidney disease, with a urinary albumin-to-creatinine ratio of >300 to 5000 mg/g. (LLM, conf=0.94)

  cites [257] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med source

In the paper

“The effect of dapagliflozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (299).”

What the sources say

• Supported

  The Outcomes section (p. 6) says dapagliflozin’s effect on the primary outcome was generally consistent across prespecified subgroups, including patients without diabetes. The Discussion (p. 8) adds that it was as effective in patients without type 2 diabetes as in those with diabetes. (LLM, conf=0.95)

  cites [299] McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med source

In the paper

“Additional data from the CREDENCE trial with canagliflozin showed a 39% reduction in hospitalization for heart failure and a 31% reduction in the composite of cardiovascular death or hospitalization for heart failure, in a population with CKD and albuminuria (UACR >300-5,000 mg/g) (257).”

What the sources say

• Supported

  The Results report a hazard ratio of 0.61 for hospitalization for heart failure, equivalent to a 39% lower relative risk with canagliflozin. The Methods specify that participants had type 2 diabetes, chronic kidney disease, and an albumin-to-creatinine ratio greater than 300 to 5000 mg/g. The Secondary and Exploratory Outcomes section also reports a hazard ratio of 0.69 for cardiovascular death or heart-failure hospitalization, matching the citing sentence’s 31% reduction. (LLM, conf=0.94)

  cites [257] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med source

In the paper

“A prespecified secondary outcome was death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure, which was reduced by 13% in the finerenone group.”

What the sources say

• Supported

  The Outcomes section defines the key secondary outcome as the stated cardiovascular composite. Primary and Key Secondary Outcomes reports 367 events with finerenone versus 420 with placebo—approximately 13% fewer events—although its hazard ratio of 0.86 corresponds to a 14% lower hazard. (LLM, conf=0.86)

  cites [285] Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med source

In the paper

“In the CANVAS Program, hospitalization from heart failure was reduced by 33% in people allocated to canagliflozin, and only 14% of individuals enrolled had a prior history of heart failure (256).”

• Also stated in: § GLP-1 Receptor Agonist Trials · plain

  “Similarly, in CANVAS and DECLARE-TIMI 58, there were 33% and 27% reductions, respectively, in hospitalization for heart failure with SGLT2 inhibitor use versus placebo (256,258).”

What the sources say

• Supported

  The hospitalization-for-heart-failure figure (p. 654) reports a hazard ratio of 0.67 for canagliflozin versus placebo, equivalent to a 33% lower hazard. The baseline-characteristics table also reports that 14.4% of participants had a history of heart failure, consistent with the citing sentence’s rounded 14%. (LLM, conf=0.94)

  cites [256] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med source

In the paper

“The incidence of heart failure hospitalization occurred less in the finerenone-treated group, and only 7.7% of study participants had a prior history of heart failure.”

What the sources say

• Supported

  The Primary and Key Secondary Outcomes section identifies hospitalization for heart failure as a component of the cardiovascular outcome and states that its incidence was lower with finerenone than with placebo. The quoted claim concerns that comparison, not the separate statement about participants’ prior history of heart failure. (LLM, conf=0.92)

  cites [285] Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med source

In the paper

“lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59-0.83]),”

What the sources say

• Supported

  The RESULTS section (p. 2) reports fewer first worsening heart failure events with dapagliflozin than with placebo and gives the exact hazard ratio and 95% confidence interval claimed. (LLM, conf=0.95)

  cites [299] McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med source
• ?Not checked — no full text of the sourcecites [307] American Diabetes Association Professional Practice Committee, 2024, 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2024, Diabetes Care source

In the paper

“Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65-0.85]),”

What the sources say

• Supported

  The Outcomes section (p. 6) defines the primary outcome as worsening heart failure or cardiovascular death and reports a lower incidence with dapagliflozin than with placebo. It gives the claimed hazard ratio of 0.74 and 95% CI of 0.65 to 0.85. (LLM, conf=0.95)

  cites [299] McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med source
• ?Not checked — no full text of the sourcecites [307] American Diabetes Association Professional Practice Committee, 2024, 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2024, Diabetes Care source

In the paper

“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56-0.90]).”

What the sources say

• Supported

  The FIGARO-DKD paper reports in “Effects on Primary Composite Outcome and Components” that hospitalization for heart failure was less frequent with finerenone than placebo, with the exact hazard ratio and confidence interval quoted. No page number is available in our copy. (LLM, conf=0.95)

  cites [248] Pitt, 2021, Cardiovascular events with finerenone in kidney disease and type 2 diabetes, N Engl J Med source

In the paper

“The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) study showed that individuals treated with the DPP-4 inhibitor saxagliptin were more likely to be hospitalized for heart failure than those given placebo (3.5% vs. 2.8%, respectively) (292).”

What the sources say

• Supported

  The Cardiovascular End Points section reports more heart-failure hospitalizations with saxagliptin than with placebo: 3.5% versus 2.8%, respectively. It specifies that these percentages are 2-year Kaplan–Meier estimates. (LLM, conf=0.95)

  cites [292] Scirica, 2013, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med source

In the paper

“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76-0.98];P = 0.03) in people with type 2 diabetes and CKD (248).”

What the sources say

• Supported

  The 'Effects on Primary Composite Outcome and Components' section reports the same four-part primary outcome and a significantly lower incidence with finerenone than placebo (HR 0.87; 95% CI 0.76–0.98; P = 0.03). The Methods section identifies the trial population as patients with type 2 diabetes and CKD. (LLM, conf=0.95)

  cites [248] Pitt, 2021, Cardiovascular events with finerenone in kidney disease and type 2 diabetes, N Engl J Med source

In the paper

“However, three other cardiovascular outcomes trials-Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (293), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (294), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (295)-did not find a significant increase in risk of heart failure hospitalization with D”

What the sources say

• ?Not checked — no full text of the sourcecites [293] Zannad, 2015, Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet source
• Supported

  The citation to this paper is attached to TECOS, not to the claims about EXAMINE or CARMELINA. The Discussion (p. 8) reports that hospitalization-for-heart-failure rates did not differ between the sitagliptin and placebo groups. (LLM, conf=0.94)

  cites [294] Green, 2015, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes, N Engl J Med source
• Supported

  The citation to this paper is attached to CARMELINA, so the relevant part of the sentence is its finding, not the findings of EXAMINE or TECOS. In Exploratory CV Analyses (page not provided), CARMELINA reports no significant difference in heart-failure hospitalization between linagliptin, a DPP-4 inhibitor, and placebo (HR 0.90; 95% CI 0.74–1.08; P=.26). (LLM, conf=0.94)

  cites [295] Rosenstock, 2019, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial, JAMA source

In the paper

“No increased risk of heart failure hospitalization has been identified in the cardiovascular outcomes trials of the GLP-1 RAs lixisenatide, liraglutide, semaglutide, exenatide once weekly, albiglutide, or dulaglutide compared with placebo (261,264,265,296,297).”

What the sources say

• Partly supported

  The Discussion reports fewer heart-failure hospitalizations with liraglutide than with placebo, although the difference was not significant. This supports the liraglutide portion of the sentence, but this paper does not establish the heart-failure hospitalization results for the other listed GLP-1 receptor agonists. (LLM, conf=0.90)

  cites [261] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [264] Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet source
• Supported

  The Abstract Results report that hospitalization for heart failure did not differ significantly between once-weekly exenatide and placebo. This confirms the exenatide portion of the multi-cited sentence; this source is not being used to establish the results for every drug listed. (LLM, conf=0.94)

  cites [265] Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med source
• Supported

  This source is the semaglutide trial cited among several trials, so the relevant part of the claim concerns semaglutide. In Other Outcomes (Table 2; page not available), hospitalization for heart failure occurred in 59 semaglutide recipients and 54 placebo recipients; the hazard ratio was 1.11 (95% CI, 0.77–1.61; P=0.57). The trial therefore did not identify a statistically significant increase. (LLM, conf=0.91)

  cites [296] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med source
• Supported

  The Discussion reports a neutral effect of lixisenatide on hospitalization for heart failure, including among patients with and without a history of heart failure. This supports the lixisenatide portion of the multi-citation sentence; this source is not being used to establish results for the other named drugs. (LLM, conf=0.92)

  cites [297] Pfeffer, 2015, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome, N Engl J Med source

In the paper

“Similar results were obtained in clinical trials with empagliflozin (303).”

What the sources say

• Supported

  The Discussion explicitly compares the empagliflozin trial with DAPA-HF and says that, in both trials, the benefit on the primary composite outcome was driven mainly by fewer hospitalizations for heart failure. It also notes differences in the cardiovascular-death estimates, so the results were similar rather than identical. (LLM, conf=0.92)

  cites [303] Packer, 2020, Cardiovascular and renal outcomes with empagliflozin in heart failure, N Engl J Med source

In the paper

“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”

What the sources say

• Supported

  The Conclusions state that DELIVER found dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction. The Discussion likewise reports fewer worsening heart failure events and cardiovascular deaths than with placebo. This supports the citing sentence’s broad description of a similar benefit for heart failure outcomes. (LLM, conf=0.94)

  cites [302] Solomon, 2022, Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction, N Engl J Med source

In the paper

“However, the relatively small percentage of such individuals enrolled (only 21% of participants had ejection fraction >50%) and the early termination of the trial limited the ability to determine the effects of sotagliflozin in HFpEF specifically (309).”

What the sources say

• Partly supported

  Statistical Analysis (p. 4) reports that 256 of 1,222 participants—about 21%—had an ejection fraction of ≥50%, not >50% as claimed. The Discussion (p. 10) says early termination and the small preserved-ejection-fraction subgroup made firm conclusions about treatment effects difficult. (LLM, conf=0.86)

  cites [309] Bhatt, 2021, Sotagliflozin in patients with diabetes and recent worsening heart failure, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“There are multiple proposed pathways through which SGLT inhibition results in ketosis (increased b-hydroxybutyrate and acetoacetate), such as increased production due to reduction in insulin doses, increases in glucagon levels leading to increased lipolysis and ketone production, and decreased renal clearance of ketones (310,311).”

What the sources say

• ?Not checked — no full text of the sourcecites [310] Peters, 2016, Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes, Diabetes Care source
• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [311] Danne, 2019, International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors, Diabetes Care source

In the paper

“In addition to the hospitalization and mortality benefit in people with heart failure, SGLT2 inhibitors improve clinical stability and functional status in individuals with heart failure (301,(304)(305)(306).”

What the sources say

• Partly supported

  The Discussion (page unavailable) reports that dapagliflozin improved symptoms, physical limitations, and exercise function over 12 weeks in patients with heart failure with preserved ejection fraction, supporting the functional-status portion. It does not establish improved clinical stability: the Exploratory clinical endpoints section reports the same number of heart-failure hospitalizations or urgent visits in both groups. The claim also generalizes this dapagliflozin finding to SGLT2 inhibitors and individuals with heart failure broadly. (LLM, conf=0.84)

  cites [301] Nassif, 2021, The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial, Nat Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion reports that empagliflozin maintained clinical stability in patients with heart failure and reduced ejection fraction. The Results also report higher odds of improvement in NYHA functional class with empagliflozin. The citing sentence extends these findings to SGLT2 inhibitors and people with heart failure generally, without the drug and reduced-ejection-fraction qualifications of this trial. (LLM, conf=0.86)

  cites [304] Packer, 2021, Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial, Circulation sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion (page unavailable) reports fewer heart-failure events and improved symptoms and quality of life after empagliflozin initiation, supporting a clinical benefit. The Methods and Results (pages unavailable) use a total symptom score rather than a direct measure of functional status; patients had also been stabilized before treatment. The claim therefore extends the trial’s findings beyond what it measured and beyond its hospitalized acute-heart-failure population. (LLM, conf=0.84)

  cites [305] Voors, 2022, The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial, Nat Med sourceExperimental — accuracy not yet measured
• Supported

  The Results > Outcomes section reports fewer moderate-or-greater symptom deteriorations with canagliflozin than with placebo and improvements in most KCCQ domains. The Discussion explicitly concludes that SGLT2 inhibitors improve symptoms and function in patients with heart failure; it does not claim an improvement in measured step counts. (LLM, conf=0.88)

  cites [306] Spertus, 2022, The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial, Nat Med source

In the paper

“Conversely, weight loss improves symptoms of HFpEF (322).”

What the sources say

• Partly supported

  The Conclusion reports improved heart-failure symptoms after gastric bypass–induced weight loss in women with obesity-related HFpEF. The citing sentence omits those population and intervention limits, presenting the finding as applying to weight loss and HFpEF generally. (LLM, conf=0.84)

  cites [322] Mikhalkova, 2018, Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction, Obesity (Silver Spring) sourceExperimental — accuracy not yet measured

In the paper

“In addition, in the confirmatory secondary end point, semaglutide treatment improved 6-min walk distance.”

What the sources say

• Partly supported

  The Abstract reports that improved 6-minute walk distance was a confirmatory secondary result: the estimated difference versus placebo was 14.3 m. However, the source identifies its study as STEP-HFpEF DM, in patients with type 2 diabetes, rather than the STEP-HFpEF trial named in the claim. (LLM, conf=0.86)

  cites [323] Kosiborod, 2024, Semaglutide in patients with obesity-related heart failure and type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“Approximately 45% of people admitted for HFpEF have diabetes, and most people with HFpEF have obesity (320,321).”

What the sources say

• ?Not checked — no full text of the sourcecites [320] Echouffo-Tcheugui, 2016, Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry, Am Heart J source
• Partly supported

  The Discussion (Clinical and Demographic Characteristics; page unavailable) mentions diabetes in the HFpEF cohort but gives no 45% figure for people admitted with HFpEF. The Results (Baseline Characteristics; page unavailable) report that 41.3% of the cohort had obesity, while more than 83% had either overweight or obesity; thus the paper does not establish that most had obesity. (LLM, conf=0.85)

  cites [321] Haass, 2011, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial, Circ Heart Fail sourceExperimental — accuracy not yet measured

In the paper

“ultimately no evidence of heterogeneity of treatment effect by ejection fraction was noted.”

What the sources say

• Supported

  The Discussion (p. 10) explicitly states that the SOLOIST-WHF trial found no evidence of heterogeneity of treatment effect according to ejection fraction. It cautions that early termination and the small preserved-ejection-fraction subgroup precluded a firm conclusion about benefit in that subgroup; the citing sentence does not claim one. (LLM, conf=0.95)

  cites [309] Bhatt, 2021, Sotagliflozin in patients with diabetes and recent worsening heart failure, N Engl J Med source

In the paper

“Finally, in a pooled analysis from both FIDELIO-DKD and FIGARO-DKD, treatment with finerenone reduced the composite of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization for heart failure was reduced (249).”

What the sources say

• Supported

  The Methods and results passage identifies FIDELITY as a pooled analysis of two trials and defines the cardiovascular composite. The Results report fewer composite events with finerenone than placebo (825 versus 939; HR 0.86, 95% CI 0.78–0.95). (LLM, conf=0.95)

  cites [249] Agarwal, 2022, Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis, Eur Heart J source

In the paper

“In the SOLOIST trial, sotagliflozin initiated during or shortly after hospitalization in people with diabetes also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (309).”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [309] Bhatt, 2021, Sotagliflozin in patients with diabetes and recent worsening heart failure, N Engl J Med source

In the paper

“and the mean body weight was reduced by 9.8% in the group assigned to semaglutide compared with 3.4% with placebo.”

What the sources say

• Partly supported

  The Abstract reports mean body-weight changes of −9.8% with semaglutide and −3.4% with placebo, matching the quoted figures. It identifies the study as STEP-HFpEF DM, in patients with type 2 diabetes, rather than the STEP-HFpEF trial named in the claim. (LLM, conf=0.86)

  cites [323] Kosiborod, 2024, Semaglutide in patients with obesity-related heart failure and type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“After 1 year of treatment, the mean change in the score was 13.7 points with semaglutide and 6.4 points with placebo,”

What the sources say

• Partly supported

  The Abstract reports the stated 52-week mean changes in the Kansas City Cardiomyopathy Questionnaire clinical summary score: 13.7 points with semaglutide and 6.4 with placebo. It identifies the study as STEP-HFpEF DM, however, not STEP-HFpEF; the claim omits that distinction. (LLM, conf=0.88)

  cites [323] Kosiborod, 2024, Semaglutide in patients with obesity-related heart failure and type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“The primary end point of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure was reduced with sotagliflozin.”

What the sources say

• Supported

  The Discussion (p. 9) states that sotagliflozin lowered the composite primary end point of cardiovascular deaths, heart-failure hospitalizations, and urgent heart-failure visits compared with placebo. The Results (p. 2) report 5.6 versus 7.5 primary end-point events per 100 patient-years. (LLM, conf=0.95)

  cites [284] Bhatt, 2021, Sotagliflozin in patients with diabetes and chronic kidney disease, N Engl J Med source

In the paper

“No randomized trials have been specifically designed to assess the impact of cardiovascular risk reduction strategies in people with type 1 diabetes.”

In the paper

“However, in people with diabetes, there was a significant 51% reduction in the treatment group with a goal diastolic blood pressure of <80 mmHg compared with a goal diastolic blood pressure of <90 mmHg.”

What the sources say

• ?Not checked — no full text of the sourcecites [42] Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet source

In the paper

“The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial revealed that treatment with perindopril and indapamide to an achieved systolic blood pressure of $135 mmHg significantly decreased cardiovascular event rates compared with a placebo treatment with an achieved blood pressure of 140 mmHg (41).”

What the sources say

• ?Not checked — no full text of the sourcecites [41] Patel, 2007, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, Lancet source

In the paper

“The committee recognizes that there has been no randomized controlled trial to specifically demonstrate a decreased incidence of cardiovascular events in people with diabetes by achieving a blood pressure <130/80 mmHg.”

In the paper

“The primary end point, a composite of cardiovascular death, nonfatal stroke or MI, or new or worsening renal or eye disease, was reduced by 9% in the combination treatment.”

What the sources say

• ?Not checked — no full text of the sourcecites [41] Patel, 2007, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, Lancet source

In the paper

“People with diabetes may present with a wide spectrum of heart failure, including heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmEF), or heart failure with reduced ejection fraction (HFrEF) (12).”

What the sources say

• ?Not checked — no full text of the sourcecites [12] Heidenreich, 2022, 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation source

In the paper

“Notably, there is an absence of high-quality data available to guide blood pressure goals in people with type 1 diabetes, but a similar blood pressure goal of <130/80 mmHg is recommended in people with type 1 diabetes.”

In the paper

“As discussed below, treatment should be individualized, and treatment goals should not be set to achieve <120/80 mmHg, as a mean achieved blood pressure <120/80 mmHg is associated with adverse events.”

In the paper

“In this trial, the primary composite outcome of stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes occurred in 3.5% of individuals in the intensive treatment group versus 4.6% in the standard treatment group (hazard ratio [HR] 0.74 [95% CI 0.60-0.92];P = 0.007).”

What the sources say

• ?Not checked — no full text of the sourcecites [37] Xie, 2016, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet source

In the paper

“Notably, most of the evidence supporting interventions to reduce cardiovascular risk in diabetes comes from trials of people with type 2 diabetes.”

In the paper

“Numerous studies have shown the efficacy of managing individual cardiovascular risk factors in preventing or slowing ASCVD in people with diabetes.”

In the paper

“Therefore, in addition to the management of hyperglycemia, hypertension, and hyperlipidemia, treatment with SGLT2 inhibitors and/or GLP-1 RAs that have demonstrated benefit is considered a fundamental element of risk reduction and the pharmacological strategy to improve cardiovascular and kidney outcomes in people with type 2 diabetes (Fig. 10.1).”

In the paper

“Multiple-drug therapy is often required to achieve blood pressure goals (Fig. 10.2), particularly in the setting of CKD in people with diabetes.”

In the paper

“An analysis of trials including people with type 2 diabetes and impaired glucose tolerance with achieved systolic blood pressures of <135 mmHg in the intensive blood pressure treatment group and <140 mmHg in the standard treatment group revealed a 10% reduction in all-cause mortality and a 17% reduction in stroke (35).”

What the sources say

• ?Not checked — no full text of the sourcecites [35] Bangalore, 2011, Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials, Circulation source

In the paper

“Extrapolation of these studies suggests that people with diabetes may also be more likely to benefit from intensive blood pressure management when they have high absolute cardiovascular risk.”

In the paper

“Single-pill antihypertensive combinations may improve medication taking in some individuals (66).”

What the sources say

• ?Not checked — no full text of the sourcecites [66] Bangalore, 2007, Fixed-dose combinations improve medication compliance: a meta-analysis, Am J Med source